Equities analysts predict that Epizyme Inc (NASDAQ:EPZM) will post sales of $1.13 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Epizyme’s earnings, with the highest sales estimate coming in at $1.25 million and the lowest estimate coming in at $1.00 million. The company is expected to report its next earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that Epizyme will report full-year sales of $7.77 million for the current year, with estimates ranging from $5.00 million to $15.00 million. For the next fiscal year, analysts forecast that the company will post sales of $35.90 million, with estimates ranging from $5.18 million to $70.90 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow Epizyme.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.17.
Shares of NASDAQ:EPZM traded up $0.24 during trading on Monday, hitting $12.39. The stock had a trading volume of 784,069 shares, compared to its average volume of 928,946. Epizyme has a 12-month low of $5.14 and a 12-month high of $18.70. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -7.20 and a beta of 3.15.
Institutional investors have recently bought and sold shares of the stock. Quantamental Technologies LLC acquired a new stake in Epizyme during the fourth quarter worth about $43,000. Legal & General Group Plc grew its holdings in Epizyme by 16.9% during the fourth quarter. Legal & General Group Plc now owns 10,060 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 1,455 shares during the period. JGP Global Gestao de Recursos Ltda. acquired a new stake in Epizyme during the fourth quarter worth about $76,000. Two Sigma Advisers LP acquired a new stake in Epizyme during the fourth quarter worth about $76,000. Finally, Metropolitan Life Insurance Co. NY grew its holdings in Epizyme by 326.5% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 16,541 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 12,663 shares during the period. 72.63% of the stock is currently owned by hedge funds and other institutional investors.
Epizyme Company Profile
Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.
See Also: 52-Week High/Low
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.